NSE: INDIAGLYCO · BSE: 500201 · ISIN INE560A01023
India Glycols Limited stock analysis
India Glycols Limited ranks #988 in the TickerSutra evidence-ranked universe with a score of 58/100 and 95% data confidence. The latest captured fundamentals show ROCE of 12.4%, quarterly sales growth of 8.6% and quarterly profit growth of 32.2%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Strong CFO/EBITDA of 1.18×
- 16.7% three-year sales CAGR
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Debt/equity is above 0.5×
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹2,868cr | ₹269cr | ₹340cr | 9.0% |
| 2023 | ₹2,651cr | ₹305cr | ₹141cr | 12.0% |
| 2024 | ₹3,294cr | ₹415cr | ₹173cr | 13.0% |
| 2025 | ₹3,768cr | ₹511cr | ₹231cr | 14.0% |
| 2026 | ₹4,211cr | ₹649cr | ₹293cr | 15.0% |
| TTM | ₹4,301cr | ₹669cr | ₹316cr | 16.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
India Glycols Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineGeneral UpdatesNSE · 22 Sept 2026India Glycols Limited has informed the Exchange about General Updates
RoutineIndia Glycols Ltd - 500201 - Intimation Of Schedule Of Analyst / Institutional Investor Meeting.BSE · 22 Sept 2026Please find attached.
MANAGEMENT COMMENTARY
Signals from filed documents
However, the raw material availability and pricing continue to be volatile and a challenge in Q2 as well. In nicotine, there has been growth and there has been capacity expansion. Nicotine sales grew two times quarter-over-quarter driven by customer conversions in Europe.
So, Ennature Bio Pharma, as I mentioned, achieved its best-ever quarterly performance at INR83 crores, growth of over 65% in the prior quarter. Thiocolchicoside sales registered a robust growth of 26% over the prior quarter, previous quarter, supported by a strong order pipeline, improved price realization. However, the raw material availability and pricing continue to be volatile and a challenge in Q2 as well.
So, all in all, strong revenue and EBITDA growth, strong margin performance, business restructuring on plan. As far as potable spirits is concerned, the broader theme of premiumization and market leadership continues. On the chemicals front, we have had a good growth across areas, and we’ll talk about the factors subsequently.
So, this growth has been supported by new acquisitions of customers, several nutraceutical launches, expansion of the nicotine business, and in general, improved efficiency. The finance costs for the company declined to INR25 crores in Q1 FY27 from INR45 crores in Q1 FY26, and this is on account of debt reduction which has been supporting the profitable growth as well. Debt levels had reduced during the quarter and d
So, that's a broader point I'd like to make. Now, coming to another important thing is as we have got the approval from NCLT for the demerger. As you know, NCLT has now sanctioned the scheme of arrangement on 17th of July 2026, and upon effectiveness, the Spirits, Bio-Fuel, and Bio Pharma undertaking transfer to dedicated resulting companies.
So, we see in terms of our drivers, one is our strength in process chemistry, product development, applications, and partnerships. So, a lot of our new value-added chemicals are being driven by innovation and applications where we are essentially moving from product to good product to differentiated product to understanding applications to solving problems to collaborative projects to strategic projects, and you can
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…